Study identifier:D5980R00105
ClinicalTrials.gov identifier:NCT06511193
EudraCT identifier:N/A
CTIS identifier:N/A
Chronicling the COPD Patient Journey and change in impact of a single inhaler combination therapy on COPD symptoms, quality of life and exacerbations following initiation of Budenoside/Glycopyrronium/Formoterol [BGF](CHRONICLES COPD)
Chronic obstructive pulmonary disease (COPD)
Phase 4
No
Budenoside/Glycopyrronium/Formoterol
All
200
Observational
35 Years - 130 Years
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Aug 2024 by AstraZeneca
AstraZeneca
Asthma Research Group Inc., University Health Network
No locations available
Arms | Assigned Interventions |
---|---|
Budenoside/Glycopyrronium/Formoterol Patients with COPD who initiate BGF as prescribed by physician per the approved country-specific label and reimbursement criteria | - |